Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Stockholders' Equity (Deficit)

v3.10.0.1
Note 5 - Stockholders' Equity (Deficit)
6 Months Ended
Dec. 31, 2018
Notes To Financial Statements [Abstract]  
Stockholders' Equity (Deficit)

Private Placement of Common Stock

 

In December 2018, our Board of Directors approved the private placement of up to 4,545,455 shares of our common stock to select accredited investors for a total amount of $5,000,000, or $1.10 per share of common stock with the right of the Board to increase the offering amount to $7,000,000 (the “Offering”). On December 26, 2018, we completed an initial closing of the Offering, pursuant to which we sold an aggregate of 3,359,100 shares of common stock, at $1.10 per share, for an aggregate purchase price of $3,695,010 in cash. A portion of the proceeds from the Offering was used to repay in full approximately $2.6 million in borrowings and accrued interest under two short-term credit facilities provided by Cleveland Capital, L.P. and a shareholder. The shares offered and sold in the Offering have not been registered under the Securities Act of 1933, as amended (“Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The shares were offered and sold to the accredited investors in reliance upon exemptions from registration pursuant to Rule 506(c) of Regulation D promulgated under Section 4(a)(2) under the Securities Act.

 

Advisory Agreement

 

Catalyst Global LLC. Effective April 1, 2018, we entered into a renewal contract (the “2018 Renewal”) with Catalyst Global LLC to provide investor relations services for 12 months in exchange for monthly fees of $4,500 per month and 34,840 shares of restricted common stock per quarter. The initial tranche of 8,710 shares was valued at $1.70 or $14,807 when issued on June 21, 2018, the second tranche of 8,710 shares was valued at $2.01 or $17,507 when issued September 28, 2018, and the third tranche of 8,710 shares was valued at $1.75 per share or $15,243 when issued on December 31, 2018. The 2018 Renewal is cancelable upon 60 days written notice.  

 

Shenzhen Reach Investment Development Co. (“SRID”). On March 14, 2018, we entered into a consulting agreement with SRID to assist us with identifying strategic partners, suppliers and manufacturers in China for a term of 12 months. Included with the services is a two-week trip to China to meet with potential manufacturers, which took place in April 2018. In consideration for the services, we agreed to issue to SRID, up to 174,672 shares of restricted common stock valued at approximately $80,000 over the course of the 12-month term. As of December 31, 2018, 145,416 shares have been issued.

  

Warrant Activity

 

Warrant detail for the six months ended December 31, 2018 is reflected below:

 

   

Number of

Warrants

   

Weighted

Average

Exercise

Price Per

Warrant

   

Remaining

Contract

Term (#

years)

 
Warrants outstanding and exercisable at June 30, 2018     1,740,790     $ 2.03       0.74  
Warrants issued     -       -       -  
Warrants exercised     (79,957 )   $ 1.48       -  
Warrants forfeited     -     $ -       -  
Warrants outstanding and exercisable at December 31, 2018     1,660,833     $ 2.06       0.19  

  

Stock-based Compensation 

 

On November 26, 2014, our board of directors approved our 2014 Equity Incentive Plan (the “2014 Plan”), which was approved by our shareholders on February 17, 2015. The 2014 Plan offers selected employees, directors, and consultants the opportunity to acquire our common stock, and serves to encourage such persons to remain employed by us and to attract new employees. The 2014 Plan allows for the award of stock and options, up to 10,000,000 shares of our common stock.

  

Activity in stock options during the six months ended December 31, 2018, and related balances outstanding as of that date are reflected below:

 

   

Number of

Shares

   

Weighted

Average

Exercise Price

   

Weighted

Average

Remaining

Contract

Term (# years)

 
Outstanding at June 30, 2018     3,544,473     $ 0.83        
Granted     401,174       1.75        
Exercised     -       -        
Forfeited and cancelled     180,000       0.46        
Outstanding at December 31, 2018     3,765,647     $ 0.95       8.48  
Exercisable at December 31, 2018     1,884,940     $ 0.83       7.69  

 

Activity in stock options during the six months ended December 31, 2017, and related balances outstanding as of that date are reflected below:

 

   

Number of

Shares

   

Weighted

Average

Exercise Price

   

Weighted

Average

Remaining

Contract

Term (# years)

 
Outstanding at June 30, 2017     716,277     $ 1.01        
Granted     1,970,000       0.46        
Exercised     -                
Forfeited and cancelled     (1,000 )     0.50        
Outstanding at December 31, 2017     2,685,277     $ 0.61       8.96  
Exercisable at December 31, 2017     1,626,613     $ 0.81       7.86  

  

Stock-based compensation expense recognized in our condensed consolidated statements of operations for the three and six months ended December 31, 2018 and 2017, includes compensation expense for stock-based options and awards granted based on the grant date fair value. For options and awards granted, expenses are amortized under the straight-line method over the expected vesting period. Stock-based compensation expense recognized in the condensed consolidated statements of operations has been reduced for estimated forfeitures of options that are subject to vesting. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

Our average stock price during the six months ended December 31, 2018 was $2.05, and as a result the intrinsic value of the exercisable options at December 31, 2018 was approximately $2,410,000.

 

We allocated stock-based compensation expense included in the condensed consolidated statements of operations for employee option grants and non-employee option grants as follows:

 

    For the Three Months Ended December 31     For the Six Months Ended December 31,  
    2018     2017     2018     2017  
Research and development   $ 17,000     $ 61,000     $ 32,000     $ 64,000  
General and administration     226,000       92,000       375,000       100,000  
Total stock-based compensation expense   $ 243,000     $ 153,000     $ 407,000     $ 164,000  

 

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of stock options was measured at the grant date using the assumptions (annualized percentages) in the table below:

 

Six months ended December 31,   2018     2017
Expected volatility   142 %-143%     100 %
Risk free interest rate   2.73 % - 2.82%     1.76 %
Forfeiture rate     20.0 %     23.0 %
Dividend yield   0 %     0 %
Expected term (years)   5     5

 

The remaining amount of unrecognized stock-based compensation expense at December 31, 2018 relating to outstanding stock options, is approximately $1,717,000, which is expected to be recognized over the weighted average period of 1.59 years.